10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript
10x Genomics, Inc. ( TXG ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Cassie Corneau - Manager of Investor Relations & Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Adam Taich - CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Madeline Mollman Puneet Souda - Leerink Partners LLC, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division David Westenberg - Piper Sandler & Co., Research Division Kyle Boucher - TD Cowen, Research Division Lu Li - UBS Investment Bank, Research Division Michael Ryskin - BofA Securities, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jaden Rismay - JPMorgan Chase & Co, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Benjamin Mee - Stephens Inc., Research Division Presentation Operator Thank you for standing by. Welcome to the 10X Genomics' Third Quarter 2025 Earnings Conference Call.
Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.3 per share a year ago.
10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Moves 11.1% Higher: Will This Strength Last?
10x Genomics (TXG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
10x Genomics, Inc. (TXG) Q2 2025 Earnings Call Transcript
10x Genomics, Inc. (NASDAQ:TXG ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Adam S. Taich - CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Cassie Corneau - Manager of Investor Relations & Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Jacob Krahenbuhl - William Blair & Company L.L.C.
10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates
10x Genomics (TXG) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to a loss of $0.32 per share a year ago.
10x Genomics (TXG) Upgraded to Buy: Here's Why
10x Genomics (TXG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think 10x Genomics (TXG) Could Surge 43.12%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 43.1% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe 10x Genomics (TXG) Could Rally 55.85%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 55.9% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
